Introduction
SLE is an autoimmune disease characterized by multiorgan manifestations, such as skin rash, arthralgias, ulcer, baldness, and autoimmune disorders. It has been well-known that cardiac involvement is often as the poor prognosis in SLE [
1,
2]. It also relates to disease severity and adverse drug reactions [
3].The cardiac manifestations can arise from endocardium, myocardium, pericardium, valves, conduction system, and vessels [
4,
5].
Cardiovascular diseases are frequent in SLE patients. There were regional and racial differences in cardiac manifestations and related risk factors in patients with SLE [
6]. The pathological and clinical characteristics of SLE have not been completely elucidated until now. Many studies about cardiac manifestations in SLE patients were focused on only few cases rather than population. Thus, cardiac manifestations and their risk predictors in Han Chinese SLE patients were explored in our study.
Study population
Seven hundred fifty SLE patients were recruited from the department of rheumatology of the Fourth Clinical Medical College and the First Affiliated Hospital of Guangzhou University of Chinese Medicine consecutively between May 2005 and May 2017. The race of all the patients was Han. The diagnosis of SLE was defined according to the American College of Rheumatology (ACR) Classification Criteria [
7]. This study complied with the Declaration of Helsinki and was approved by the Ethics Commission of Guangzhou University of Chinese Medicine.
Clinical data of all subjects, including gender, age, disease duration, autoantibodies (anti-ACA antibody, anti-SSA antibody, anti-SSB antibody, anti-dsDNA antibody, anti-Sm antibody and ANA), were collected. Transthoracic Doppler-echocardiography and troponin were used to diagnose pericardial effusion, PAH, CAD, myocarditis, and heart valve disease. The electrocardiogram was used to assess arrhythmia, CAD, and myocarditis. According to pulmonary artery systolic pressure, PAH was classified as mild (35–59 mmHg), moderate (59–89 mmHg), and severe (> 89 mmHg) [
8].
The mean age of all patients was (36.59 ± 14.52) years old, and 88.8% of the patients (
n = 666) was female. The mean disease duration was (4.72 ± 5.94) years. The positive rate of anti-ACA, anti-SSA, anti-SSB, anti-dsDNA, anti-Sm antibodies, and ANA was 5.3%, 51.7%, 15.6%, 52.5%, 30.5%, and 80.4%, respectively. Disease activity was evaluated by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [
9]. The patients were divided into two groups—those with or without cardiac manifestations.
Discussion
Cardiac involvement is a common and severe symptom in SLE patients. It has been reported that the cumulative incidence rate of cardiovascular disease in SLE increased widely [
4]. Cardiac manifestations in Chinese SLE patients have unique characteristics.
A retrospective study on PAH in 93 SLE patients found that pulmonary artery pressure (PAP) elevated in 13% of SLE patients (including White, Black, North Africa, and Other races) by noninvasive assessment [
10]. And among the cases, morbidity, anti-Sm, and anti-cardiolipin antibodies were statistically different. The PAH-related morbidity in SLE patients was similar to the result of our study (15.7%); however, there were no differences in autoantibodies between the two studies.
The mechanism of arrhythmias in SLE patients has not been completely understood. The reports about the specific antibodies in arrhythmias, such as anti-Ro/SSA and anti-RNP, were controversial [
11‐
13]. In our study, SLEDAI was the predictor of arrhythmias. SLEDAI may be correlated with pericarditis, myocarditis, atherosclerotic myocarditis, and small vessel vasculitis with collagen and fibrotic deposits, which leads to abnormality of conduction system [
14,
15].
Previous studies have shown the prevalence of heart valve disease in SLE has ranged from 12 to 73% [
16‐
21]. Vivero et al. found that valve lesions could be seen in 25% of Caucasian SLE patients, and age was the predictor of valvular thickening and dysfunction [
22], while the prevalence of this report was higher than that of our study (15.6%). Similarly, age was also as the predictor in Vivero et al.’s report [
22]. Valvulitis and cicatrisation could promote the development of thickening and deformation of vessels, resulting in valvular dysfunction in elderly SLE patients [
23].
Pericarditis is one of the most common cardiac manifestations in SLE. Approximately 25% of SLE patients developed symptomatic pericarditis [
24,
25]. Autopsy studies revealed even a higher incidence rate of subclinical pericarditis in SLE [
25].The morbidity of SLE patients in other races was higher than Chinese SLE patients. Inflammatory exudate with neutrophil predominance and autoantibodies were found in pericardial effusion of SLE patients. Histopathology of pericarditis often found immune complex deposition, monocytes, and fibrinous substance [
26,
27]. In our study, age was confirmed to be the predictor of pericarditis in SLE patients.
A recent study have shown morbidity of CVD was the highest among the blacks (10.57%) and lowest among the Asians (6.63%) [
28]. The percentage of morbidity in Asian SLE patients was 3%, with a tenfold risk compared to the general population and a 50-fold risk at reproductive age [
29,
30]. But CVD-related morbidity of in Chinese SLE patients was lower in our study. The risk factors included oxidized low-density lipoprotein, autoantibodies against endothelial cells and phospholipids, type I interferons (IFN-I), and extracellular neutrophils [
31]. SLEDAI was the predictor of CVD in our study, which may be affected by immunological regulation.
The autopsy studies showed that subclinical myocarditis may commonly occur in 57% of SLE patients. It can be the initial cardiac manifestation during the progression of SLE in, particularly, among the untreated patients [
32]. A French study showed that myocarditis was the first symptom in 58.6% of SLE patients [
33], while 5.7% of Chinese SLE patients suffered from myocarditis in our study. Steroids and cyclophosphamide provide therapy for lupus myocarditis [
34,
35]. Some reports showed that plasmapheresis [
36] or high dose of intravenous immunoglobulin treatment [
37] could improve myocarditis in SLE patients.
The wide use of glucocorticoid and immunosuppressive agents has improved symptoms and survival of SLE patients. However, glucocorticoids can increase the risk of lupus cardiovascular disease and cardiac death. Until now, the status of cardiovascular diseases in Han Chinese SLE patients has not been clarified. In this study, we selected SLE patients with disease duration ≤ 10 years and found that the risk factors for cardiac death of Han Chinese SLE patients were PAH and myocarditis. PAH significantly decreased survival time and quality of life in patients with connective tissue diseases [
38]. A meta-analysis of six studies including 323 SLE patients accompanying PAH, which were carried out in the UK, the USA, China, and Japan, demonstrated that 1-, 3-, and 5-year survival rate was 88%, 81%, and 68%, respectively [
39]. Apte et al. analyzed myocarditis in multiethnic cohorts of the USA and found that 53 of 496 SLE patients had myocarditis, and myocarditis was associated with short life span, particularly in patients with disease duration ≥ 5 years [
40].
Our study had some limitations. It was a retrospective study and needed to be further verified. The assessment methods of heart diseases were not strictly unified, so only indirect detection was used to evaluate cardiac diseases in SLE patients. The effects of treatment on heart diseases in SLE were not assessed, which need to explore in the further study.
In conclusion, we confirmed cardiac manifestations are common in Han Chinese SLE patients. Age and disease activity increase the risk of cardiac manifestations. PAH and myocarditis are the risk predictors of mortality in SLE patients.